about ctsc

Case Western Reserve University, in partnership with the Cleveland Clinic, University Hospitals and MetroHealth Medical Center formed the Clinical & Translational Science Collaborative (CTSC) in September 2007.

The National Institutes of Health (NIH) awarded the partners $64 million to become part of a national consortium designed to transform how clinical and translational research is conducted, ultimately enabling researchers to provide new treatments more efficiently and quickly to patients.

The consortium, funded through NIH's Clinical and Translational Science Awards, was formed in 2006 with an initial 12 academic health centers located nationwide.

Leadership

Peter B. Lewis Building
Pamela B. Davis, M.D., Ph.D.

The CTSC is lead by Pamela B. Davis, dean and vice president for medical affairs of the Case Western Reserve University School of Medicine and principal investigator, and Richard A. Rudick, vice chair of the Neurological Institute at the Cleveland Clinic and co-principal investigator.

Peter B. Lewis Building
Richard A. Rudick, M.D.

Mission

The ultimate goal of the CTSC is to provide full service and integrated clinical translational research capability within the Cleveland community that will improve the health of patients in Northeast Ohio through patient-based research. The CTSC also provides career development support for clinical investigators and offers each research participant resources in support of technology-intensive studies. In addition, the CTSC will create new resources for current and future investigators and for the Cleveland community, including:

  • Community partnership programs
  • A coordinated bioinformatics infrastructure
  • An M.D-Ph.D. program in clinical research
  • Coordinated resources in bioethics and regulatory support

About Clinical and Translational Science Awards

The CTSA initiative grew out of the NIH commitment to restructure the clinical research enterprise, one of the key objectives of the NIH Roadmap for Medical Research. Funding for the CTSA comes from redirecting existing clinical and translational programs, including Roadmap funds. When fully implemented in 2012, the initiative is expected to provide more than $500 million over five years to 60 academic health centers.